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Increasing evidence suggests that inflammatory and immune components in brain are important in Alzheimer’s
disease (AD) and anti-inflammatory and immunotherapeutic approaches may be amenable to AD treatment. It is
known that complement activation occurs in the brain of patients with AD, and contributes to a local inflammatory
state development which is correlated with cognitive impairment. In addition to the complement’s critical role in
the innate immune system recognizing and killing, or targeting for destruction, complement proteins can also
interact with cell surface receptors to promote a local inflammatory response and contributes to the protection and
healing of the host. On the other hand, complement activation also causes inflammation and cell damage as an
essential immune function to eliminate cell debris and potentially toxic protein aggregates. It is the balance of
these seemingly competing events that influences the ultimate state of neuronal function. Our mini review will be
focusing on the unique molecular interactions happening in the AD development, the functional outcomes of
those interactions, as well as the contribution of each element to AD.Introduction
The brain has been considered an immunologically
privileged organ in part due to the presence of the blood–
brain barrier (BBB), which prevents the entry of blood-
born cells and other immune molecules from peripheral
system into the central nervous system (CNS). However,
multiple evidence indicates that this privilege is not abso-
lute “sealed” from peripheral immune system. Studies
demonstrated various immune and inflammatory mecha-
nisms operating actively within the brain, particularly in
response to disease or injury [1-10]. These findings have
opened a new view of neuroimmunology and also brought
great opportunities to develop novel agents that may pre-
vent various neurodegenerative disorders as Alzheimer’s
disease (AD), Parkinson’s disease (PD), multiple sclerosis
(MS), AIDS dementia complex (ADC), amyotrophic lat-
eral sclerosis (ALS) and stroke. This mini-review focuses
only on the role of the complement system in AD.
Alzheimer’s disease (AD) is a chronic neurodegenera-
tive disorder with characterization by extracellular senile* Correspondence: yshen@rfdn.org; rli@rfdn.org
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reproduction in any medium, provided the orplaques, intracellular neurofibrillary tangles and neur-
onal loss [11-15]. The major component of senile
plaques is amyloid-β-peptide (Aβ), a group of 39–43
amino acid peptides derived from the amyloid precursor
protein (APP) [11,12,16,17]. The fact that Aβ is detected
in both normal and AD brains [16] indicates that Aβ
alone may not be sufficient to cause AD. In recent years,
the occurrence of inflammatory proteins in the AD brain
has been widely reported [1,3-9,18-24]. One prominent
feature of AD neuropathology is the association of acti-
vated proteins of the classical complement pathway with
the lesions [1,5,25-28]. The full range of classical path-
way complement proteins from C1q to C5b-9 (mem-
brane attack complex, MAC), has been found highly
localized with compacted or β-pleated Aβ deposits in
neuritic plaques [4-7,26,28,29]. The complement cas-
cades have been activated to the last step the MAC stage
indicates that the regulatory mechanisms of the comple-
ment system have been unable to halt the complement
activation process to avoid brain tissue. Some comple-
ment regulators have been found in association with the
AD lesions [7,25,27,28,30,31]. This is a further proof of
complement activation in the lesions but also an indica-
tion that the regulators have been able to control com-
plement activation only to a limited extent.d. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in the pathogenesis of AD have been documented for a
long time [9,22,32-35]. From a therapeutic point of view,
several direct studies on twins [32] and a recent “ibuprofen”
clinical trial [34] have provided evidence that nonsteroidal
anti-inflammatory drugs (NSAIDs) are one potential means
of reducing inflammation in AD. Similar results were also
obtained from a small double-blind, placebo-controlled trial
using Indomethacin for AD prevention, a common NSAID
[33,35]. Clinical trials of NSAIDs in AD patients have not
been very fruitful lately. But in epidemiological studies that
treatment with NSAIDs decreases the risk for developing
AD [36]. NSAIDs are not very effective direct inhibitors of
complement but they can inhibit the inflammatory conse-
quences of complement activation, particularly those that
are mediated by mast cells and other leukocytes [37].
Roles of complement activation in alzheimer’s
disease
Activation of any of three complement pathways
(classical, lectin or alternative pathway) in the human
body is very important in normal inflammatory re-
sponses to injury and in removing invading microbes.
It is also a very important clean-up system in remov-
ing apoptotic cells, tissue debris and macromolecular
aggregates. However, complement activation can also
cause cell injury or death when activated inappropri-
ately. Thus, although complement activation may not be
the primary etiology of many diseases it can be responsible
for many of the disease manifestations. Indeed, inappropri-
ate complement activation has been recognized as an im-
portant pathogenetic factor in many cardiovascular,
immune, renal and neurological diseases. In the nervous
system, inflammation and neurodegeneration in AD are par-
tially mediated by complement activation [1,5-7,26,38,39].
In comparison, in multiple sclerosis, which is a largely T-cell
-mediated disease, complement seems to be important in
causing demyelination and damage of oligodendrocytes
[40,41].
Complement cascade activated by pathological
hallmarkers in Alzheimer’s brains
The complement cascade can be activated in the AD
brain based on the evidence that Aβ-initiated, antibody-
independent, complement activation in AD. The pioneer
works were done by Rogers’ work and Tenner’s
experiments by using Aβ binds C1q and activates the
classical complement pathway [5,18,38,42,43]. This dis-
covery provides preliminary a theory how inflammation
arises and be sustained throughout the course of AD,
since Aβ, possibly oligomer Aβ, is present from early
stage to terminal stages of the disorder. Apparently, the
classical pathway tries to remove the Aβ-protein
deposits but fails in this task. Thus, continuingcomplement activation persists and causes inflammation.
As discussed above, most studies determining inflam-
mation characteristics for the AD brain have centered
on the interactions of Aβ with complement proteins
and other mediators of inflammation [44]. However,
neurofibrillary tangles, the other classical pathological
hallmark for AD, could play an equally important role
in the neuropathology of AD. Our previous studies
demonstrate that purified neurofibrillary tangles activate
the complement system in plasma, resulting in a signifi-
cant increase in the levels of soluble terminal comple-
ment complexes (SC5b-9) [8]. Like Aβ, the aggregated
tau, a major component of neurofibrillary tangles, may
also be a potent antibody-independent activator of the
classical complement pathway [8,45].
The activated complement components have significant
pro-inflammatory activities. For example, the complement
C3 is cleaved into C3b and C3a. C3b remains bound to the
complex at the surface of the trigger. C3b is a good opso-
nin. The small peptide, C3a diffuses away and acts as a
chemotactic factor and an inflammatory paracrine. The
generation of complement anaphylatoxins, notably C5a,
activates leukocytes and induces the production of pro-
inflammatory cytokines, which could be toxic or trophic
depending on their target cells and receptor molecules
[6,7,30,46-54]. The local production of complement pro-
teins, from C1q to C9, has been found to be increased in
the AD and other neurodegenerative disease brain
[2,6,26,50,54-57]. Complement activation also results in
the generation of other activation products, the opsonins,
which label target cells for attack by phagocytes. The opso-
nins, C1q, C4b and C3b/iC3b, have been found in AD
brain samples [18,20,27,30,57]. Furthermore, the formation
of the complement membrane attack complex, the MAC,
on the membranes of neuronal cells can result in their lysis
[6,7,21,46]. Finally, MAC attack on neuronal and glial cells
can also cause significant immunological activation of the
cells with many unexpected consequences.
The significance of the complement activation in AD
is not only the pathological changes in the terminal
stage of AD but also reflects the early alternation in the
disease course, i.e. mild cognitive impairment (MCI).
For example, Loeffler et al. [58] have performed studies
on iC3b, C9, Bielschowsky and Gallyas staining in in
brains with 18 AD, 12 MCI with that from 17 aged normal
controls and identified iC3b, C9, and Bielschowsky-stained
plaque counts increased 2.5- to 3-fold in AD compared to
MCI and control subjects. C9 staining was present on
some diffuse plaques, as well as on neuritic plaques. Inter-
estingly, Bielschowsky- complement-co-localized plaque
counts were highly correlated. When the Bielschowsky
plaque count was used as a predictor, its correlations with
cognitive measures were statistically significant. This is a
direct piece of pathological evidence linked with clinical
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iC3b, and late-event, final complement component
protein, C9, appear in neocortical plaques in subjects
across the cognitive spectrum; Moreover, C9 is ob-
served in diffuse plaques. Due to high correlations be-
tween complement and Bielschowsky co-stained
plaque counts, quantitative assessment of the extent
to which complement activation may mediate the re-
lationship between plaques and cognitive function.
Recently Benoit et al. found that in mouse model,
C1q pathways were up-regulated in vivo early in re-
sponse to injury, induced a program of gene expres-
sion that promotes neuroprotection and thus might
provide protection against Aβ in preclinical stages of
AD and other neurodegenerative processes [59]. A poten-
tial clinical trial by using an inhibitor of late-stage comple-
ment activation, if there was any, in AD patients would be
able to confirm the significance of this process in AD.Neurodegeneration mediated by complement activation
and mechanisms
In vitro, Aβ binds C1q and activates the classical comple-
ment pathway [5,37,43,60]. Thereby Aβ can induce
complement-mediated toxicity against neurons in culture
[6,7,21,47]. This suggests that Aβ-induced complement
activation may contribute to the neuropathogenesis in AD
[4,25]. In APP+PS1 transgenic mice, Clq injections In-
creased fibrillar beta-amyloid [61]. MAC complexes have
been detected in the AD brain, and their generation
in vitro by Aβ stimulation leads to consequences that one
would predict for a pathophysiologically relevant mechan-
ism in AD [6,7].
Normally C5 convertases, generated by either the clas-
sical or the alternative pathway, initiate the activation of
the terminal pathway of the complement system. This
leads to the formation of the cytolytic MAC. The MAC is
a macromolecular complex made up of complement com-
ponents C5b, C6, C7 and C8 plus multiple C9 molecules.
Once formed, the ring-like structure of the MAC consti-
tutes a pore on the membrane of the target cells, permit-
ting influx of Ca2+, Na+, small molecules and water. This
can lead to subsequent osmotic cell lysis or to a metabolic
“storm” within the cell. Neuroimmune regulatory proteins
(NIReg) may control the adverse immune responses in
health and diseases. NIRegs are found mainly on neurons,
glia, endothelia and ependymal cells and include GPI-
anchored molecules (CD24, CD90, complement regulators
CD55 and CD59), molecules of the immunoglobulin
superfamily (siglec CD22, Siglec 10, CD200, ICAM-5) and
others (CD47, fractalkine, TAM receptor tyrosine kinase
and complement C3a and factor H). These regulators
modulate the innate immune response in the CNS and for
instance critically control the level of phagocytosis andinflammation engaged by resident microglia and infiltrat-
ing immune cells [62].
Complement-containing human serum shows no signifi-
cant toxicity against human neuronal cells, although it
kills rat and mouse neurons [47]. As reported previously,
the lack of susceptibility to human serum toxicity was ap-
parently due to the presence of species-selective comple-
ment regulatory proteins such as complement inhibitors
CD55, CD59 on the cell surface (a phenomenon referred
to as homologous restriction). Since two complement
inhibitors, CD55 and CD59, are glycosylphosphatidyl-
inositol (GPI)-anchored cell membrane proteins, we
examined the susceptibility of human neurotypic cells,
SH-SY5Y, to human complement attack after treat-
ment with phosphatidylinositol-specific phospholipase
C (PIPLC). Indeed, human neuronal cells were suscep-
tible to killing by human complement only after re-
moval of GPI-anchored cell membrane proteins by
PIPLC. In agreement with the LDH release measure-
ments, the neurotoxic effect of human serum on PIPLC-
pretreated cells was confirmed by morphological changes
typical of injured neurons. One of the proteins removed
by PIPLC is CD59, a membrane-bound glycoprotein cap-
able of protecting against complement-mediated lysis by
preventing the assembly of MAC [6,7,47,63-66]. As
expected, PIPLC-pretreated SH-SY5Y neurotypic cells
were also susceptible to human MAC-induced lysis and a
significant increase in LDH release was observed after one
day incubation with the equivalent of 4 hemolytic units of
MAC [28,47]. These results suggested that neurons might
be more vulnerable to complement-mediated Aβ toxicity
when CD59 is dysfunctional or its levels on the cell sur-
faces are reduced.
To prevent MAC attack, CD59 forms a complex with
C5b-8, thereby preventing further assembly of the poly-
C9 MAC and its insertion into the cell membrane
[63-65]. CD59 is widely distributed in human cells
[6,7,27,47,63-65]. It has been found in many types of
cells, including neurons, astrocytes, epithelial and endo-
thelial cells [6,7,27,30,47,52,64,65]. Relative to other cell
types, its expression by oligodendrocytes has been low.
The mature CD59 protein contains 77 amino acids after
removal of the signal sequence and the signal for the
GPI-anchor. Its gene is located in the p14-p13 region
on the short arm of chromosome 11 [66]. CD59 is at-
tached to the cell membrane through a GPI-anchor, in-
stead of having a transmembrane domain [67]. The site
for the GPI-anchor attachment of CD59 is the most
carboxy-terminal amino acid Asn-77 [63]. As discussed
above, MAC inhibition by CD59 occurs if the MAC
components are from the same species as the target cell
[47,63]. Conversely, when the complement source and
the target cells are from different species, CD59 may
not always inhibit the MAC. Because of this species-
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occur, if the cells and complement are from different
species. We observed CD59 expression in neuronal cells
by detecting specific CD59 DNA by an oligonucleotide
probe in PCR-Southern blot hybridization. The expres-
sion of the CD59 protein in neurotypic cells was confirmed
by immunofluorescence staining. The expression became
significantly reduced upon PIPLC treatment [30,47].
Gasque’s and Morgan’s groups [68,69] observed that
human fetal neurons expressed some CD59, but were
expressed much higher levels in astrocytes [48,68,70].
Thus, human fetal neurons appear to be more vulnerable
to complement activation than astrocytes. Decreased levels
or absent CD59 may permit MAC formation and lead to
nonspecific complement lysis. This is the case in paroxys-
mal nocturnal hemoglobinuria (PNH), where a proportion
of bone marrow-derived cells lack GPI-anchored CD59
and CD55. Our recent studies suggest that similar condi-
tions are present in the AD brain. As a consequence, in-
creased MAC formation, deposition and cell lysis as a
result of a deficient CD59 regulatory activity could play a
pathophysiologic role in AD neurodegeneration [6,7].
Because of the cell stimulating and destructive capabil-
ities of the MAC, a rigorous analysis of reasons for its for-
mation in the AD brain is extremely important. Also, the
extent of expression and properties of CD59 in the AD
brain must be defined, since a deficiency in CD59 could
render even moderate MAC formation, a potent neurode-
generative mechanism. Although a cellular source for
MAC components has not been conclusively defined, the
identification, both of proteins and mRNAs, of MAC com-
ponents in the AD brain suggests that a proportion of
them could be endogenously produced [6,7,20,26,51].
Since some of the complement components (e.g., C1q) are
relatively large in size and charged [60], their passage from
blood through an intact BBB could be restricted. In vitro,
astrocytoma cell lines and primary astrocytes, as well as
microglia, have been shown to produce complement pro-
teins, suggesting that glial cells may be an endogenous
source within the brain [6,7,70,71]. This is especially true
for microglial cells, since they are closely related to macro-
phages, a cell type known to manufacture complement
components [72]. Perhaps surprisingly, recent evidence
[51,70], including that from our laboratory [6,7,26], sug-
gests that neurons and certain neuroblastoma lines may
produce virtually the full range of classical pathway com-
ponents. To what end they might do so, and under what
conditions, is still unclear.
Virtually all cells in the body can become targets for
complement attack. So they must have developed a rela-
tively wide range of defenses, including CD59 expression.
From this concept, we have discovered phenomena so
called “homologous restriction” between human species
and other rodent species [26], which protect our humanbeing protect ourselves against self-complement attack
[45]. Therefore, endogenous CD59 production by both
neurons and glia in the brain would be expected because
of “homologous restriction” we just discussed above. It is
true that complement regulatory proteins can be found in
the brain parenchyma and are increased, especially under
acute inflammatory conditions, i.e. meningitis. However,
in the condition for chronic inflammatory case, i.e. AD,
the expression levels of complement regulatory proteins
may be at a low level. We previously discovered that
CD59 is deficient in the AD brains [7] and believe that this
possibly dues to either inflammatory molecules down-
regulate complement regulatory proteins or some endogen-
ous enzymatic-like molecules cleave of the GPI-anchored
proteins, including CD59 [7], which allow complement cas-
cades are activated, leading to sustained activation of glial
cells or neuron death or both.
Potential therapeutic targets to complement activation in
Alzheimer’s disease
Based upon these immunological findings, complement
inhibitors could possibly provide an alternative thera-
peutic means as neuroprotective agents or as anti-
neuroinflammatory agents in treating AD or other CNS
disorders, where complement activation is involved.
They can act at different levels of complement activa-
tion and have distinct properties. In the following, a
couple of examples are provided.
Inhibition of the serine proteases of the complement system
The complement system is a proteolytic cascade, where
serine proteases activate each other by limited proteoly-
sis in a strictly ordered manner. Serine proteases are es-
sential in both the initiation and the amplification of the
cascade. Since uncontrolled complement activation con-
tributes to the development of serious disease condi-
tions, inhibition of the complement serine proteases
could be an attractive therapeutic approach. Major types
of serine protease inhibitors include (a) macroglobulins,
(b) serpins and (c) canonical inhibitors. Macroglobulins
and serpins are large proteins which undergo major con-
formational change during the inhibition process and
form irreversible complex with the target proteases. The
canonical inhibitors are small proteins which occupy the
active site and form very tight but thermodynamically re-
versible complex with the target proteases. C1-inhibitor
(C1INH) is a good example. C1INH a natural comple-
ment protease inhibitor, which is approved for clinical use
in hereditary angioedema (HAE) [73]. Sequence compari-
sons and functional analyses have indicated that C1INH
α1-antitrypsin, α2-antiplasmin, antithrombin III and plas-
minogen activator inhibitor types I and III belong to the
superfamily of serine protease inhibitors or serpins [74].
C1INH is a plasma glycoprotein of 105 kD with gene
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components C1r and C1s of the classical pathway of
complement activation through the formation of an
inhibitor-protease complex [76]. The complex is formed
between the reactive center of the C1INH amino-
terminus and the active site of the protease. In the central
nervous system, C1INH has been identified in neurons.
Like in other serpins, the reactive region of serpins mimics
the substrate of the protease. One hypothesis proposes
[31,52] that inactivation of the C1INH may play a role in
local inflammatory reactions and pathological circum-
stances. The level of C1INH is decreased in type I (HAE),
a disorder inherited in an autosomal dominant fashion. In
patients with type II HAE, mutated dysfunctional C1INHs
are found [52]. In the AD brain, both C1INH mRNA and
protein have been identified [19,31]. C1INH has not only
been found in neurons but also in microglial cells and as-
trocytes [31]. Interestingly, these studies have demon-
strated that C1INH is present in inactive form in activated
microglia and astrocytes. Moreover, C1INH has also been
detected in abnormal neuronal processes, such as dys-
trophic neurites in the AD brain [31]. Eikelenboom [39]
and Veerhuis [19] found that interferon-gamma stimu-
lated C1INH protein secretion in the AD brain but IL-1β,
IL-6 and TNF-α could only stimulate C1INH synthesis at
the mRNA, but not at the protein level [1,39]. Thus, a
block in C1INH synthesis could occur at the level of trans-
lation. Moreover, in situ hybridization studies demon-
strated that C1INH mRNA was primarily expressed in
neurons, indicating that neurons may be an important
source for complement regulatory proteins in vivo. Be-
cause of its biological properties C1INH may be used as a
possible therapeutic agent. C1INH preparations have
been used e.g. in the treatment and prevention of HAE
attacks, and to suppress inflammation in the ischemia-
reperfusion syndrome that is associated with myocardial
infarction [77].
Complement receptor type 1 (CR1, C3b/C4bC receptor
or CD35)
Complement receptor type 1 (CR1) can be detected on
blood cell surfaces by immunofluorescence imaging
techniques. For example, counting CR1 numbers in
granulocytes by FACS, is used for monitoring the extent
of systemic neutrophil and monocyte activation [45]. A
soluble form of CR1 (sCR1) can be detected in serum at
the ng/ml level, a concentration that already can inhibit
pathological complement activation. Because of its po-
tency, recombinant soluble CR1 has been considered as a
complement-inhibiting drug [48,70]. In the central ner-
vous system, administration of sCR1 in rats resulted in a
40% decrease in brain neutrophil accumulation in the
traumatized hemisphere as compared to normal controls
[52,78]. sCR1 was first studied in myocardial infarction[79] and it has been suggested as a therapy to prevent re-
jection of xenotransplants and in various inflammatory
diseases. Thus, sCR1 is a feasible and potent complement
inhibitor, of which experience on use in vivo is available.
Recently, genome-wide association studies (GWAS)
identified that the CR1-S isoform has been associated
with AD and is considered a novel AD gene [80]. The
analyses of brain samples demonstrated that the CR1-S
isoform protein expression is at lower protein levels
than CR1-F (p < 0.0001) hence likely associated with in-
creased complement activation [81]. Interestingly, the
pathological results demonstrate the different expres-
sion patterns of CR1 in neurons between the F/F and
F/S genotypes. Moreover, double-labeling studies
supported such differential distributions of CR1 in
endoplasmic reticulum intermediate compartment
compared to lysosomes in neurons. These findings sug-
gest that the CR1-S and CR1-F isoforms process
differentially in different ways in neurons and provide a
novel prospect for the investigation of CR1-related
mechanisms for AD.Proteoglycans as inhibitors of C1q binding
Proteoglycans are heavily glycosylated proteins. They
are a type of molecule found in connective tissue and
considered as potential therapeutic molecules for many
diseases. C1q combines with the enzymes C1r and C1s
to form C1, the first component of the classical comple-
ment pathway [82]. C1q can bind to immunoglobulins
and to non-immunoglobulin classical pathway activa-
tors such as the Aβ peptide [2,5,18,39,43,60,83]. C1q
also binds to apoptotic cells and substances released
from injured cells, like mitochondria, cytoskeletal fila-
ments and chromatin. C1q binding initiates activation
of the classical complement cascade, which ultimately
leads to MAC formation and target cell lysis [6,21,47].
C1q deposits are often found in injured tissues. Thus, it
would appear logical to design and develop drugs to
block C1q binding so that the complement cascade is
inhibited at an early stage [84,85]. Chondroitin sulfate
proteoglycans (CSPG) have recently been found in hu-
man B cell line supernatants [86]. The secreted CSPGs
bound strongly to C1q but cellular CSPGs did not. The
binding of CSPG to solid-phase-bound C1q could in-
hibit formation of the C1 complex with C1r and C1s.
Thus, CSPG could offer a tool for inhibiting C1 activa-
tion, but so far, all experiments have been done only
in vitro. CSPG has a broad spectrum of activities. An-
other drawback is that inhibition of C1q binding could
compromise the normal cleaning function of the clas-
sical pathway. It is well known that C1q deficiency in
man and experimental gene knock-out animals leads to
a severe form of systemic lupus-like disease [87].
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FUT-175 (nafamstat) is a potent synthetic serine protease
inhibitor. It has potent anti-complement activity in vitro. It
can inhibit the activity of C1r and C1s proteases but has no
inhibitory effect on the C2a protease activity [2]. Clinically,
the administration of FUT-175 intravenously to patients
with complement activation associated glomerulonephritis
resulted in a significant decrease in urinary protein excre-
tion and in an increase in the levels of serum complement
proteins C3 and C4 [88]. Syringin (TC-4) and cordiol
(TC-7), derived from an Indian plant, also have
anticomplementary and immunomodulatory activities.
Recently, it was discovered that these two compounds
inhibit the C3 convertase of the classical complement
pathway [89,90]. Recently Holmquist et al. discovered
Sushi domain-containing protein 4 (SUSD4) is a novel
complement inhibitor and it inhibited the formation of
the classical C3 convertase by 90% [91].
Other putative complement inhibitors such as fucans,
naturally sulfated polysaccharides, have been isolated from
brown seaweed [92,93]. Fucans inhibit the classical path-
way by interfering with C1 activation or by inhibiting C3
cleavage [94] by the classical pathway C3 convertase. They
may also inhibit the alternative pathway C3 convertase by
suppressing factor B binding to C3b and destabilizing pro-
perdin function [94]. However, fucans have no effect on
the formation of the MAC [94].
Cerebral amyloid angiopathy (CAA) has similar AD
pathologies associated with Aβ accumulation and inflam-
mation in the brain. Zabel et al. [95] has examined human
post-mortem brains with concomitant CAA and AD with
purely parenchymal pathology and for differential expres-
sion of microglia-associated Aβ ligands thought to medi-
ate Aβ clearance and the association of these receptors
with complement activation. They found that C3b and
MAC were significantly increased in CAA compared to
AD-only and controls and immunoprecipitation (IP)
showed significantly increased CD11b/C3b complexes (in
microglia) with Aβ in AD/CAA subjects. Immunohisto-
chemical studies with confocal microscopy reveal these
interactions. MAC was remarkably associated with CAA-
affected blood vessels compared to AD-only and control
vessels. These findings suggest an Aβ clearance mechan-
ism via microglial CD11b that delivers Aβ and C3b to
blood vessels in CAA (maybe AD as well), which leads to
Aβ accumulation and propagation of complement to the
cytolytic MAC, possibly leading to vascular fragility [95].
Microglia is a microphage of the brain, and abnormal
activation of microglia in cascades result in neuronal loss
and cognitive decline in AD [72]. As described before, Re-
cent GWAS have indicated a number of risk factors, CR1,
for the development of late-onset AD, which may impli-
cate microglial responses in AD during the course of com-
plement activation in the brain. Changing complementreceptor expression may result in disorder of the comple-
ment activation cascade, no matter over-activated different
complement pathways or imbalances between comple-
ment factor production and complement cascade inhibi-
tors, which may contribute to the involvement of
complement in AD. Moreover, abnormal complement sig-
naling may reduce the ability of microglia to phagocytose
apoptotic cells and clear Aβ peptides, modulate the ex-
pression by microglia of complement components and re-
ceptors, promote complement factor production by
plaque-associated cytokines derived from activated micro-
glia and astrocytes, and disrupt complement inhibitor
production.
C5 activation blockers or C5a receptors
The C5 activation product, C5a, is a 4-helix bundle glyco-
protein containing 74 amino acids. It is a strong chemo-
tactic agent for neutrophils, macrophages and microglia
and activates mediator release from many cell types, not-
ably from mast cells. C5a exerts its primary physiological
and pathological effects by binding to its specific G-
protein coupled C5a receptor (C5aR; CD88). This leads to
triggering of signal transduction and powerful inflamma-
tory responses [96-98]. The presence of C5a receptors on
neurons and glia in the brain raises the possibility that they
might respond to locally generated C5a [7,26,68,70,71,99].
Gasque et al. found that the C5a receptor is expressed in
the human brain and particularly in astrocytes [48]. Because
C5a is an important mediator of inflammation, C5a recep-
tor antagonists could have therapeutic potential. Recently, a
series of high-affinity, basic benzodiazepine ligands for the
C5a receptor have been developed [100]. Because these
ligands are more basic (pKa = 9.48) than the previous li-
gands, their aqueous solubility has been significantly im-
proved. The IC50 values of these compounds for C5aR are
< 2.5 nM. However, the inhibitory effects of benzodiaze-
pines on C5a receptor activity have not been extensively
reported, neither in vitro nor in vivo. To specifically inhibit
C5aR, a small peptide derived from the C5a hexapeptide C
terminus has been recently reported [101]. Analyses of the
antagonist’s tertiary structure and the effects of point muta-
tions demonstrate a positively charged contact surface
composed of Arg 75, Arg 46, Lys 49 and His 15 residues.
The importance of this surface in providing antagonist
properties implies a single binding site in the C5a receptor
protein [102]. It would be important to examine whether
these compounds have any effects in the central nervous
system.
One of the most promising specific complement inhibi-
tors for clinical use is the humanized anti-C5 antibody,
pexelizumab, produced by the Alexion corp [103]. This
antibody blocks the cleavage of C5, thereby inhibiting both
C5a generation and MAC assembly, which is initiated
upon C5b formation. Importantly, the earlier complement
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that early classical pathway-mediated solubilization of pro-
tein aggregates, possibly including also those of Aβ, and
opsonization for phagocytosis are left intact. Theoretically,
this antibody would appear as ideal for suppressing C5a-
and MAC-mediated inflammation, although it may not
help in the solubilization or removal of Aβ-aggregates by
the earlier parts of the complement cascade.
Since AD is associated with neuroinflammation, acti-
vation of astrocytes and microglia, and evidence of acti-
vation of the complement system, localized with both
fibrillar Ab (fAb) plaques and tangles. Using the com-
pound PMX205 to inhibit the major complement recep-
tor for C5a (CD88) leads to less pathology in mouse
models of AD. While thioflavine plaque load and glial
recruitment is significantly reduced after treatment with
PMX205, C1q remains co-localized with fAbeta plaques
and C3 is still expressed by the recruited astrocytes.
Thus, with PMX205, potentially beneficial activities of
these early complement components may remain intact,
while detrimental activities resulting from C5a-CD88
interaction are inhibited [104]. This further supports the
targeted inhibition of specific complement mediated ac-
tivities as an approach for AD therapy.
Neuroimmune regulatory proteins
NIReg contributes to the adverse immune responses in
health and diseases. NIRegs are found mainly on neu-
rons, glia, endothelia and ependymal cells. They include
sialic acids, GPI-anchored molecules (CD24, CD90, com-
plement regulators CD55 and CD59), molecules of the im-
munoglobulin superfamily (siglec CD22, Siglec 10, CD200,
ICAM-5) and others (CD47, fractalkine, TAM receptor
tyrosine kinase and complement C3a and factor H). These
regulators contribute to control the innate immune re-
sponse in the CNS. Some of NIRegs could be potential
therapeutical molecules [62,105-108]. Griffith et al. found
that accumulation of human factor H in the brain paren-
chyma protected neurons from complement opsonization,
axonal injury, and leukocyte infiltration [109]. Axonal
damage secondary to inflammation is found in the animal
model of experimental autoimmune encephalomyelitis
(EAE). Wld(s) mice have a triplication of the fusion gene
Ube4b/Nmnat and a phenotype of axon protection. Wld
(s) mice develop an attenuated disease course of EAE,
with decreased demyelination, reduced axonal pathology,
and decreased CNS macrophage and microglial accumula-
tion. The attenuated disease in Wld(s) mice was associated
with higher expression of the nonsignaling CD200 mol-
ecule on neurons in the CNS compared with control mice.
In vitro, Wld(s) neuronal cultures were protected from
microglial-induced neurotoxicity compared with control
cultures, but protection was blocked by anti-CD200 anti-
body. CD200 interacts with its signaling receptor CD200R.Then CD200-CD200R pathway plays a critical role in at-
tenuating EAE and reducing inflammation-mediated dam-
age in the CNS. Strategies that up-regulate the expression
of CD200 in the CNS or molecules that ligate the CD200R
may be relevant as neuroprotective strategies in multiple
sclerosis [105].
Decay-accelerating factor (DAF, CD55) inhibits com-
plement activation by suppressing the function of C3/
C5 convertases, thereby limiting local generation or de-
position of C3a/C5a and MAC production. When com-
pared to controls, hypoxic cells had fewer dendritic
spines, reduced plateau depolarization accompanied by
increased apoptotic activity and accumulation of MAC,
as well as up-regulation of C3, C3a and C3aR, enhance-
ment of C3a-C3aR engagement, and elevated caspase
and Src activity. Treatment of hypoxic cells with 200
ng/ml of recombinant human DAF resulted in attenu-
ation of neuronal apoptosis and exerted significant pro-
tection against neuronal dendritic spine loss and plateau
depolarization reduction. Furthermore, treatment with
DAF resulted in decreased accumulation of C3a, MAC,
C3a-C3aR interaction, caspase-9, activated caspase-3,
and pTyr416-Src (activated Src) tyrosine kinase. DAF
was found to reduce neuronal cell death and apoptosis
in NaCN induced hypoxia [107].
CD59 expression is regulated by the neural-restrictive si-
lencer factor (REST). A designed novel REST-derived pep-
tide (REST5) containing the nuclear localization domain of
the wild-type protein was used to observe this regulation.
REST5 increased the expression of CD59 in neurons by
fivefold and protected them from complement-mediated
lysis spontaneously triggered by neurons [108].
Complement proteins as potential biomarkers
and vaccination of AD
Complement proteins may use potential biomarkers for AD
As previous described, the complement cascade is an es-
sential element of the innate immune response. In the
brain complement proteins are integral components of
plaques (i.e. C1q binds Aβ) or tangles (aggregated tau
binds C1q). Complement activation can occur at the very
early stage of the disease. Therefore, certain complement
components for complement activation act as potential
biomarker for AD during the disease process [110].
Wang et al. [111] recently examined complement 3 and
factor H (alternative complement pathway complement fac-
tor) in human cerebrospinal fluid in AD, compared to other
neurological controls such as PD and multiple-system atro-
phy. Interestingly, they found that both C3 and FH corre-
lated with the severity of cognitive impairment in AD.
A study was conducted recently with four single nucleo-
tide polymorphisms (SNPs) in complement genes and
cerebrospinal fluid (CSF) biomarkers for AD in 452
neurochemically or neuropathologically verified AD cases
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sociated with risk of AD but there were potential associa-
tions of rs9332739 in the C2 gene and rs4151667 in the
complement factor B gene with CSF tau levels (p = 0.023)
and Mini-Mental State Examination scores (p = 0.012),
both of which may be considered markers of disease in-
tensity/severity [112].
Because there is a deficiency of CD59 GPI anchored
proteins in AD brains [7] due to the cleavage of these
proteins from brain cells, it is possible that the CD59
proteins flow into the CSF and plasma when the blood–
brain-barrier BBB is damaged in AD patients. We exam-
ined CD59 levels in CSF from postmortem patients and
found an increase compared to ND controls (Figure X).
Conversely, complement C9 component is the final com-
ponent to be added into the C5b-8 subcomplex of MAC.
We previously discovered that C9 levels were significantly
elevated in the same regions where the CD59 protein is
deficient in AD brains [7]. If the final complement compo-
nent C9 is heavily deposited in AD brains, the AD brain
acts like a toxin sink to trap many toxins, including C9,
resulting in low levels of C9 in the CSF. Indeed, we
detected the decrease of C9 protein level from postmor-
tem patients with AD (Figure XX). Identifying an accurate
biomarker that has sufficient predictive, diagnostic and
prognostic value would provide a significant opportunity
to develop and test for effective novel therapies in the
treatment of AD [111,113].
Vaccination as an alternative treatment of
Alzheimer’s disease
Amyloid beta protein plays a pivotal role in AD onset and
progression and secondary consequences of Aβ generation
and deposition, including tau hyperphosphorylation and
neurofibrillary tangle formation, oxidation, inflammation,
and excitotoxicity, contribute to the disease process. Inter-
ventions in these processes with agents that reduce amyl-
oid production, limit aggregation, or increase removal or
vaccination and immunization might block the cascade of
events comprising AD pathogenesis [114]. In the past few
years, studies on experimental vaccines have been
conducted [69,99,115-117]. A number of passive immu-
nizations with anti-Aβ42 antibodies are in different
phases of clinical trials. One active immunization ap-
proach, AN-1792 (consisting of preaggregate Aβ and an
immune adjuvant, QS-21), was stopped after the devel-
opment of autoimmune encephalitis in 6% of patients
and a second one, CAD106, in which a small Aβ epitope
is used, is currently in safety and tolerability studies. Be-
sides active immunizations with proteins or peptides,
active immunizations using DNA which codes for the
protein against which the immune response will be di-
rected, so called genetic immunizations, provide add-
itional safety as the immune response in DNAimmunizations differs quantitatively and qualitatively from
the response elicited by peptide immunizations [117-121].
Anti-Aβ monoclonal antibodies (bapineuzumab and
solanezumab) are now being developed. The clinical re-
sults of the initial studies with bapineuzumab were
equivocal in terms of cognitive benefit. Solanezumab, a
humanized anti-Aβ monoclonal antibody directed against
the midregion of the Aβ peptide, was shown to neutralize
soluble Aβ species. Phase II studies showed a good safety
profile of solanezumab, while studies on cerebrospinal and
plasma biomarkers documented good signals of pharma-
codynamic activity. The results of the large, ongoing Phase
III trials with bapineuzumab and solanezumab will tell us
if monoclonal anti-Aβ antibodies may slow down the rate
of deterioration of AD [118-123]. As we described above,
one theory of the cause of AD is the inflammation hypoth-
esis, whereby Aβ deposits in the brain induce an inflam-
matory response that activate microglia to produce toxins
and destroy surrounding neurons, which results in a cog-
nitive decline. There are three possible working hypoth-
eses for this immunization under debate. For the first
hypothesis, antibody binds to Aβ deposits and activates
the complement system, which in turn triggers receptors
on microglial cells to begin phagocytosis and remove deb-
ris or internalize Aβ [118-120]. Secondly, vaccines or anti-
bodies dissolve the Aβ containing plaques directly,
which would release monomeric Aβ, causing activation
of microglial cells through some scavenger receptors on
the surface of microglia. Thirdly, antibodies act as an
“Aβ sink” in the peripheral system to enhance clearance
of Aβ [124-126]. These possibilities have been compre-
hensively reviewed from different aspects in recent re-
views [118,121-123,126-128]. The main message of this
mini-review is that complement can have dual effects in
Alzheimer’s disease. In the negative aspect complement
activation by Aβ or tau causes neurodegeneration,
whereas in the positive aspect complement is important
for the tissue clearance functions. Since these functions
are partially mediated by different parts of the comple-
ment cascade, any therapeutic interventive approaches
should be appropriately focused and thoroughly tested
before use.
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